skip to main content
Idioma:
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Elsevier ScienceDirect Journals remover Base de dados/Biblioteca: Oxford University Press:Jisc Collections:Medicine Collection:2018 remover Base de dados/Biblioteca: ScienceDirect remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
Material Type:
Artigo 		Adicionar ao Meu Espaço

Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary

Tanizaki, J. ; Yonemori, K. ; Akiyoshi, K. ; Minami, H. ; Ueda, H. ; Takiguchi, Y. ; Miura, Y. ; Segawa, Y. ; Takahashi, S. ; Iwamoto, Y. ; Kidera, Y. ; Fukuoka, K. ; Ito, A. ; Chiba, Y. ; Sakai, K. ; Nishio, K. ; Nakagawa, K. ; Hayashi, H.

Annals of oncology, 2022-02, Vol.33 (2), p.216-226 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
1089P Hepcidin expression as a predictive biomarker for anti-PD1/PDL1 antibody monotherapy for advanced non-small cell lung cancer
1089P Hepcidin expression as a predictive biomarker for anti-PD1/PDL1 antibody monotherapy for advanced non-small cell lung cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

1089P Hepcidin expression as a predictive biomarker for anti-PD1/PDL1 antibody monotherapy for advanced non-small cell lung cancer

Yamamoto, M. ; Kubo, S. ; Hirama, N. ; Teranishi, S. ; Tashiro, K. ; Seki, K. ; Maeda, C. ; Hiro, S. ; Kajita, Y. ; Sugimoto, C. ; Segawa, W. ; Nagayama, H. ; Nagaoka, S. ; Kudo, M. ; Kaneko, T.

Annals of oncology, 2022-09, Vol.33, p.S1049-S1050 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy

Segawa, Y. ; Aogi, K. ; Inoue, K. ; Sano, M. ; Sekine, I. ; Tokuda, Y. ; Isobe, H. ; Ogura, T. ; Tsuboi, M. ; Atagi, S.

Annals of oncology, 2009-11, Vol.20 (11), p.1874-1880 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível

Citações Citado por
4
Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08)
Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08)

Tsuji, A. ; Eto, T. ; Masuishi, T. ; Satake, H. ; Segawa, Y. ; Tanioka, H. ; Hara, H. ; Kotaka, M. ; Sagawa, T. ; Watanabe, T. ; Nakamura, M. ; Takahashi, T. ; Negoro, Y. ; Manaka, D. ; Fujita, H. ; Suto, T. ; Ichikawa, W. ; Fujii, M. ; Takeuchi, M. ; Nakajima, T.

Annals of oncology, 2016-10, Vol.27, p.vi168-vi168 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Tumor sidedness and enriched gene groups for efficacy of 1st-line cetuximab (cet) treatment in metastatic colorectal cancer (mCRC)
Tumor sidedness and enriched gene groups for efficacy of 1st-line cetuximab (cet) treatment in metastatic colorectal cancer (mCRC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tumor sidedness and enriched gene groups for efficacy of 1st-line cetuximab (cet) treatment in metastatic colorectal cancer (mCRC)

Ichikawa, W. ; Mogushi, K. ; Lenz, H-J. ; Zhang, W. ; Tsuji, A. ; Takahashi, T. ; Denda, T. ; Shimada, K. ; Kochi, M. ; Nakamura, M. ; Kotaka, M. ; Segawa, Y. ; Lafleur, B. ; Luecke, J. ; Thompson, D. ; Moran, M. ; Astrow, S.H. ; Hsiang, J. ; Fujii, M. ; Sunakawa, Y.

Annals of oncology, 2017-09, Vol.28, p.v199-v200 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Assessment of the Genetic Component of Hypertension
Assessment of the Genetic Component of Hypertension
Material Type:
Artigo 		Adicionar ao Meu Espaço

Assessment of the Genetic Component of Hypertension

Yamada, Yoshiji ; Matsuo, Hitoshi ; Segawa, Tomonori ; Watanabe, Sachiro ; Kato, Kimihiko ; Hibino, Takeshi ; Yokoi, Kiyoshi ; Ichihara, Sahoko ; Metoki, Norifumi ; Yoshida, Hidemi ; Satoh, Kei ; Nozawa, Yoshinori

American journal of hypertension, 2006-11, Vol.19 (11), p.1158-1165 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
7
A Randomized Phase III Study of a Cisplatin (CDDP) and Docetaxel (DOC) with or without Irinotecan (CPT) in Patients with Advanced NSCLC: Okayama Lung Cancer Study Group OLCSG 0403 Trial
A Randomized Phase III Study of a Cisplatin (CDDP) and Docetaxel (DOC) with or without Irinotecan (CPT) in Patients with Advanced NSCLC: Okayama Lung Cancer Study Group OLCSG 0403 Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Randomized Phase III Study of a Cisplatin (CDDP) and Docetaxel (DOC) with or without Irinotecan (CPT) in Patients with Advanced NSCLC: Okayama Lung Cancer Study Group OLCSG 0403 Trial

Ichihara, E. ; Hisamoto, A. ; Harita, S. ; Segawa, Y. ; Kamei, H. ; Shibayama, T. ; Gemba, K. ; Hotta, K. ; Matsuo, K. ; Aoe, K. ; Takigawa, N. ; Tabata, M. ; Tanimoto, M. ; Kiura, K.

Annals of oncology, 2012-10, Vol.23, p.xi34 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
A Phase II Study of Cisplatin (P), S-1 (S) and Concurrent Thoracic Radiotherapy (TRT) for Locally Advanced Non-Small-Cell Lung Cancer (LA-NSCLC): Okayama Lung Cancer Study Group Trial 0501
A Phase II Study of Cisplatin (P), S-1 (S) and Concurrent Thoracic Radiotherapy (TRT) for Locally Advanced Non-Small-Cell Lung Cancer (LA-NSCLC): Okayama Lung Cancer Study Group Trial 0501
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase II Study of Cisplatin (P), S-1 (S) and Concurrent Thoracic Radiotherapy (TRT) for Locally Advanced Non-Small-Cell Lung Cancer (LA-NSCLC): Okayama Lung Cancer Study Group Trial 0501

Nogami, N. ; Kozuki, T. ; Segawa, Y. ; Shinkai, T. ; Maeda, T. ; Ueoka, H. ; Harita, S. ; Kuyama, S. ; Hosokawa, S. ; Gemba, K. ; Takemoto, M. ; Takigawa, N. ; Tabata, M. ; Tanimoto, M. ; Kiura, K.

Annals of oncology, 2012-10, Vol.23, p.xi115 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Subchronic oral toxicity of glyoxal via drinking water in rats
Subchronic oral toxicity of glyoxal via drinking water in rats
Material Type:
Artigo 		Adicionar ao Meu Espaço

Subchronic oral toxicity of glyoxal via drinking water in rats

Ueno, Hitoshi ; Segawa, Toshiharu ; Hasegawa, Tatsuya ; Nakamuro, Katsuhiko ; Maeda, Hiroshi ; Hiramatsu, Yasuzo ; Okada, Shoji ; Sayato, Yasuyoshi

Fundamental and applied toxicology, 1991-05, Vol.16 (4), p.763-772

Boston, MA: Elsevier Science (USA)

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (8)

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.